Q4 2024 Management View CEO Adam Steensberg emphasized 2024 as a transformational year for Zealand Pharma, highlighting significant clinical advancements in its obesity pipeline, particularly with ...

Unintentional weight loss prior to kidney transplant evaluation may be linked to lower listing odds and higher waitlist mortality for frail patients with obesity, a study found.“Almost all transplant ...

By keeping the metabolism continuously active, the Ice Water Hack ensures a steady energy supply throughout the day, preventing the typical mid-afternoon slump and eliminating mental fog. Many users ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

Skye Bioscience, Inc. (NASDAQ:SKYE) is making waves in the biopharmaceutical industry with its innovative approach to obesity treatment. The company's lead candidate, nimacimab, a CB1 negative ...

For the first time a semaglutide weight loss drug has been approved for use in Australia to also treat cardiovascular disease ...

As Vitality becomes the first UK insurance provider to offer discounted weight-loss jab treatment, Yahoo UK spoke to them to ...

The Independent Data Monitoring Committee met this week on February 10, 2025 to evaluate the unblinded safety Phase 2b QUALITY data and recommended to continue the QUALITY extension study as designed- ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

A study finds GLP-1 weight-loss drugs may pose vision risks, revealing an unexpected medical irony. A paradoxical insight: ...

Rapid weight loss affects muscle mass and can increase the risk of osteoporosis. But now there is good news for people taking weight loss medication who may be at risk. A new study indicates that the ...

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...